Pillstats
Rx only · For Suspension · Oral

Esomeprazole Magnesium

Esomeprazole Magnesium Dihydrate

1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US4 NDCs
1 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATC
RxCUI (US)
US makers1 labelers
Packages4
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 4 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$1.91$3.82$5.73$7.64Dec 2025Apr 2026Jul 2026
$5.340
Latest avg · Jul 22, 2026
-20%
Since Dec 17, 2025
1
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

3.6K7.2K11K14K2025 Q12025 Q22025 Q32025 Q42026 Q1
8.3K
Rx · 2026 Q1
306K
Units dispensed
+17%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it1 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Cipla USA Inc.unknown4SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Dec 17, 2020
    RECALLRecall (Class II): Esomeprazole Magnesium for Delayed-Release Oral Suspension 20mg, packaged in unit dose packets, Rx only, Manufactured b…

    Cross- contamination with other products: The excipient, Crospovidone, NF is contaminated with theophylline — Recalling firm: CIPLA — U.S.A. Nationwide

  • Dec 17, 2020
    RECALLRecall (Class II): Esomeprazole Magnesium for Delayed-Release Oral Suspension 40mg, packaged in unit dose packets, Rx only, Manufactured b…

    Cross- contamination with other products: The excipient, Crospovidone, NF is contaminated with theophylline — Recalling firm: CIPLA — U.S.A. Nationwide